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Abstract We compared the accuracy of direct susceptibil-
ity testing (DST) with conventional antimicrobial suscep-
tibility testing (AST), both using disk diffusion, on clini-
cal samples. A total of 123 clinical samples (respiratory
tract samples, urine, vaginal and abdominal abscess dis-
charges, bile fluid and a haematoma punctate) were select-
ed on various indications; direct inoculation on Mueller–
Hinton agar and antibiotic paper disks were applied. In
parallel, standard culture, identification and AST on the
colonies grown overnight was executed. Both AST and
DST were interpreted after identification of the isolates.
The results from both AST and DST for 11 antibiotics
tested on 97 samples with Gram-negative rods showed
93.4 % total agreement, 1.6 % minor discordances,
4.6 % major discordances and 0.4 % very major discor-
dances. Analysing the discordant results, DST predomi-
nantly resulted in more resistant isolates than AST. This
was mostly due to the presence of resistant mutants or an
additional isolate. The remaining discordances were seen
for isolates with inhibition zones close to the clinical
breakpoint. For the 26 samples yielding staphylococci, a
total agreement of 100 % was observed for the nine anti-
biotics tested. Overall, the highest percentage of discor-
dant results occurred for the β-lactam antibiotics amoxi-
cillin–clavulanate (13.4 %) and cefuroxime (12.4 %).
When used selectively and interpreted carefully, DST on
clinical samples is potentially very useful in the manage-
ment of critically ill patients, as the time to results is
shortened by approximately 24 h. However, we recom-
mend to communicate results with reservations and con-
firm by conventional AST.
Introduction
The identification of clinically significant bacteria in the lab-
oratory and the performance of antimicrobial susceptibility
testing (AST) provides information essential for an accurate
management of patients with a bacterial infection [1]. How-
ever, results are only available with a delay of 48–72 h after
sampling, as bacteria need to be cultured before AST can be
executed. Meanwhile, the patients must receive empirical
antibiotherapy. The diminishing and unpredictable suscepti-
bility to antibiotic agents can lead to inadequate therapy and
urges the empiric use of broad-spectrum antibiotics. De-
escalation of treatment is practised only when results from
AST are available, with immediate and long-term conse-
quences such as the emergence of multidrug-resistant micro-
organisms and an increased risk of severe superinfections,
morbidity, mortality and costs [2].
The most commonly used methods for AST are conven-
tional phenotypic methods, based on culturing on agar (e.g.
disk diffusion tests) or on microtitration plates (e.g. broth di-
lution tests) [3]. Disk diffusion has many advantages, as it is
cheap, flexible and allows visibility of growth, correct inocu-
lum, mixed cultures and other abnormalities. Another benefit
is the possibility of executing direct susceptibility testing
(DST). Aiming at a shortened turnaround time, DST has been
practised in some laboratories and reported in multiple papers
[2–21]. Nevertheless, the American Society for Microbiology
(ASM) [22], the British Society for Antimicrobial Chemother-
apy (BSAC) [23] and the European Committee on Antimicro-
bial Susceptibility Testing (EUCAST) [24] seriously criticise
DST, since the inoculum is not standardised. On the other
hand, providing clinicians with earlymicrobiological informa-
tion has a beneficial impact on the patient, permitting tailored
antibiotic use and a decrease in antimicrobial-related adverse
events [25]. Besides, previous experiments executed in our
laboratory on the comparability between AST and DST in
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respiratory samples showed promising results (unpublished
data). The aim of our study was to compare DST on clinical
samples with conventional AST, both by disk diffusion, after
the recent introduction of rapid identification by matrix-




A total of 123 clinical samples were selected on various indi-
cations, such as request by the clinician for DST, a new infec-
tion in a critically ill patient or a Gram stain showing predom-
inantly staphylococci or Gram-negative rods (GNR). The
studied specimens were 48 endotracheal aspirates, 13 sputum
samples, three bronchoalveolar lavages, 28 catheterised and
21 midstream urine specimens, two nephrostomy aspirates,
discharges from three vaginal to three abdominal abscesses,
one bile fluid and one haematoma punctate.
Culture
Urine samples were cultured on tryptic soy agar with 5 %
sheep blood (Becton Dickinson Diagnostic Systems, Sparks,
MD, USA) and MacConkey agar (Becton Dickinson Diag-
nostic Systems, Sparks, MD, USA). Respiratory tract samples
were cultured on Columbia agar with 5 % sheep blood
(Becton Dickinson Diagnostic Systems, Sparks, MD, USA),
MacConkey agar, tryptic soy agar with 5 % sheep blood and
Haemophilus chocolate 2 agar (bioMérieux, La Balme-les-
Grottes, France). The other samples were cultured on
MacConkey agar, mannitol salt agar (Becton Dickinson Diag-
nostic Systems, Sparks, MD, USA) and tryptic soy agar with
5 % sheep blood. The isolates were identified with MALDI-
TOF MS (Bruker Daltonik GmbH, Bremen, Germany).
Antimicrobial susceptibility testing
Disk diffusion ASTand DSTwas performed using paper disks
(Bio-Rad Laboratories, Hercules, CA, USA) on Mueller–
Hinton agar (Bio-Rad Laboratories, Hercules, CA, USA).
For GNR, 13 antibiotics were tested: ampicillin (AMP),
amoxicillin–clavulanate (AMC), piperacillin–tazobactam
(PPT), temocillin (TEM), meropenem (MEM), cefuroxime
(CXM), cefotaxime (CTX), ceftazidime (CAZ), gentamicin
(GEN), amikacin (AMI), ofloxacin (OFL), nitrofurantoin
(FUR) and trimethoprim–sulfamethoxazole (SXT). For staph-
ylococci, nine antibiotics were tested: penicillin (PEN),
cefoxitin (FOX), erythromycin (ERY), clindamycin (CLI), li-
nezolid (LIN), gentamicin (GEN), rifampicin (RIF),
nitrofurantoin (FUR) and trimethoprim–sulfamethoxazole
(SXT). Zones of inhibition were interpreted as susceptible
(S), intermediate susceptible (I) or resistant ®) according to
the EUCAST guidelines [26] for all antibiotics, except for
temocillin [27]. For DST, a sterile cotton swab was dipped
into a vortexed sample and inoculated onto a Mueller–Hinton
agar plate, following a massive three directions pattern. AST
with disk diffusion was executed according to the EUCAST
guidelines [26]. Both AST and DST plates were read simulta-
neously after overnight incubation at 35 °C, together with the
identification of the isolates using species-specific
breakpoints. All results were interpreted by double-blind ob-
servations by two experienced lab technicians. When two or
more pathogens were isolated, the results of DST were com-
pared with the cumulative susceptibility of the different iso-
lates found with the regular technique. Isolates recovered with
only one of two methods were marked as additional isolates.




From 42 urinary tract samples yielding GNR, 28 were
monomicrobial and 14 were polymicrobial; 24 Escherichia
coli, 11 Proteus mirabilis, nine Klebsiella pneumoniae, four
Pseudomonas aeruginosa, three Morganella morganii, three
Enterobacter cloacae, one Acinetobacter baumannii, one Pro-
teus vulgaris, oneKlebsiella oxytoca and one Proteus penneri.
From the 47 respiratory tract samples positive with GNR, 28
were monomicrobial and 19 were polymicrobial; 18
P. aeruginosa, 13 E. coli, sixK. pneumoniae, six Serratia
marcescens, fourM. morganii, three E. cloacae, three Entero-
bacter aerogenes, three P. mirabilis, twoSerratia liquefaciens,
twoS. maltophilia, one Acinetobacter spp., one Burkholderia
cepacia, one Citrobacter braakii, one Citrobacter spp., one
K. oxytoca, one Proteus spp. and one Pseudomonas spp.
strains. From the three vaginal specimens with GNR, two
were monomicrobial and one was polymicrobial; three
K. pneumoniae and one E. coli. From the three abdominal
specimens with GNR, two were monomicrobial and one was
polymicrobial; three E. coli and oneK. pneumoniae. The bile
fluid specimen yielded four different GNR:E. coli,K. oxytoca,
E. aerogenes and P. aeruginosa. The haematoma punctate was
positive for E. coli.
AST and DST from 97 clinical samples yielded 1,261 an-
tibiotic–isolate combinations. The results obtained with both
techniques were in overall agreement in 93.4 % (1,178/1,261)
of cases. The remaining comparisons showed a minor discor-
dance (S vs. I or I vs. R) in 1.6 % (20/1,261), a major discor-
dance (S in AST vs. R in DST) in 4.6 % (58/1,261) and a very
major discordance (R in AST vs. S in DST) in 0.4 % (5/1,261)
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of cases (Table 1). The discordant cases in which DSTyielded
more resistant results than AST (major discordances) are pre-
sented in lines 1 to 3 of Table 2. 87 % of those discrepancies
are explained by the recovery of resistant mutants or the pres-
ence of an additional isolate not found in the regular process-
ing of the sample. For all other discrepancies, inhibition zone
diameters were close to the clinical breakpoint, where small
differences (≤3mm) yield a different SIR result. This phenom-
enon also accounts for all of the cases where AST shows more
resistant results than DST (very major discordances), present-
ed in lines 4 to 6 of Table 2.
Staphylococci
From the 26 samples yielding staphylococci, all were
monomicrobial. From 17 respiratory tract samples, we isolat-
ed 13methicillin-susceptible Staphylococcus aureus (MSSA),
three methicillin-resistant S. aureus (MRSA) and three
S. epidermidis. From nine urinary tract samples, we isolated
thre MRSA, threeS. epidermidis, two MSSA and one
S. haemolyticus. A total of 43 clinical isolates accounted for
234 antibiotic–isolate combinations, with an overall agree-
ment of 100 %.
Table 3 summarises the overall agreement for each antimi-
crobial agent tested against GNR and/or staphylococci. The
highest percentage of discordant results occurred in the β-
lactam antibiotics AMC (13.4 %) and CXM (12.4 %). No
differences were found for FOX, PEN, ERY, RIF, CLI, FUR
and LIN.
Discussion
In our study, we compared both AST and DST by disk diffu-
sion on 123 clinical samples, mainly urine and respiratory
tract samples. The agreement for each individual antibiotic
agent always exceeded 86 %. An important thing to notice is
that, in 89 % of all discordant cases, DST showed more
resistant results than AST, mainly due to the recovery of re-
sistant mutants or an additional isolate.
Numerous studies have been published on DST on differ-
ent sample types, most of them showing excellent agreement
between AST and DST. All studies on urine samples compar-
ing both AST and DST by disk diffusion show an overall
agreement of over 90 % [4, 7, 11–13, 19]. Studies on urine
Table 1 Comparison of antimicrobial susceptibility testing (AST) and
direct susceptibility testing (DST) of the 1,261 antibiotic–isolate samples
yielding Gram-negative rods (GNR)
AST
S I R
DST S 761 (60.3 %) 2a (0.2 %) 5c (0.4 %)
I 8a (0.6 %) 14 (1.1 %) 2a (0.2 %)
R 58b (4.6 %) 8a (0.6 %) 403 (32.0 %)
aMinor discordances
bMajor discordances
c Very major discordances
Table 2 Explanation of the discordant results for GNR
RM AI BP Total
1 DST R vs. AST S 10 45 3 58
2 DST R vs. AST I 5 1 2 8
3 DST I vs. AST S 3 0 5 8
4 DST S vs. AST R 0 0 5 5
5 DST I vs. AST R 0 0 2 2
6 DST S vs. AST I 0 0 2 2
RM resistant mutant; AI additional isolate; BP inhibition zone close to
breakpoint
Line 1: major discordances; lines 2, 3, 5, 6: minor discordances; line 4:
very major discordances
Table 3 Overall agreement and reasons for discordance for each
antimicrobial agent tested for GNRa and/or staphylococcib
Agreement Discordance
RM AI BP
n % n % n % n %
Total 1,410 94.3 % 18 1.2 % 48 3.2 % 19 1.3 %
AMCa 84 86.6 % 0 0.0 % 10 10.3 % 3 3.1 %
CXMa 85 87.6 % 3 3.1 % 8 8.2 % 1 1.0 %
FURa,b 115 93.5 % 0 0.0 % 4 4.1 % 4 4.1 %
PPTa 89 91.8 % 6 6.2 % 0 0.0 % 2 2.1 %
CAZa 90 92.8 % 4 4.1 % 3 3.1 % 0 0.0 %
TEMa 91 93.8 % 0 0.0 % 3 3.1 % 3 3.1 %
OFLa 91 93.8 % 1 1.0 % 4 4.1 % 1 1.0 %
AMIa 92 94.8 % 2 2.1 % 2 2.1 % 1 1.0 %
CTXa 92 94.8 % 1 1.0 % 4 4.1 % 0 0.0 %
AMPa 93 95.9 % 1 1.0 % 3 3.1 % 0 0.0 %
MEMa 93 95.9 % 0 0.0 % 1 1.0 % 3 3.1 %
SXTa,b 119 96.7 % 0 0.0 % 4 4.1 % 0 0.0 %
GENa,b 120 97.6 % 0 0.0 % 2 2.1 % 1 1.0 %
FOXb 26 100.0 % 0 0.0 % 0 0.0 % 0 0.0 %
PENb 26 100.0 % 0 0.0 % 0 0.0 % 0 0.0 %
ERYb 26 100.0 % 0 0.0 % 0 0.0 % 0 0.0 %
RIFb 26 100.0 % 0 0.0 % 0 0.0 % 0 0.0 %
CLIb 26 100.0 % 0 0.0 % 0 0.0 % 0 0.0 %
LINb 26 100.0 % 0 0.0 % 0 0.0 % 0 0.0 %
RM resistant mutant; AI additional isolate; BP inhibition zone close to
breakpoint
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samples comparing AST by disk diffusion with DST by other
techniques (e.g. disk elution, API systems, Autobac, agar di-
lution, broth microdilution) had similar results [5, 6, 8–10, 14,
18]. Studies on respiratory tract specimens compared DST by
the Etest with AST by disk diffusion [16, 17, 21] or with AST
by broth microdilution [2, 20]. All showed an overall agree-
ment of over 85 %, except for a study on the sputa of cystic
fibrosis patients positive with P. aeruginosa [21], which
showed a poor overall agreement, especially for aminoglyco-
sides (60%). One study on intra-ocular aspirations, comparing
both AST and DST by disk diffusion, found an overall agree-
ment of 88 % [15]. The poorest results were noted in a study
on wound exudates, comparing both AST and DST by disk
diffusion [3]. The total agreement was no more than 39 %,
mainly due to inadequate growth on most of the DST plates. It
should be emphasised that the authors placed the swabs, taken
from the wound exudates, in 1 mL of tryptic soy broth, there-
by diluting the samples.
The main advantage of DST is that it offers the possibility
of obtaining results 24 h earlier than conventional AST, as has
been reported in the literature [2, 12, 15]. At that time, possible
pathogens can be identified from culture with the recently
introduced fast identification tools, such as MALDI-TOF
MS, whereby results from culture and DST can be interpreted
together. Even if susceptibility testing is incomplete, a specific
phenotype can appear, redirecting the empirically started an-
tibiotic treatment. Furthermore, the use of the whole sample
incorporates the physical characteristics of sample itself, in-
cluding mucoid bacterial phenotypes and antibiotic penetra-
tion. Thus, the results are likely to be more clinically applica-
ble. In addition, DST determines the antibiotic sensitivity for
the whole sample, rather than individual cultured colonies,
enabling an assessment of the population susceptibility to an-
tibiotics. The proof that DST indeed looks at the bigger picture
is found in our own experiments, where the recovery of resis-
tant mutants or an additional isolate explain the majority of the
discordant cases. This was particularly true for AMC and
CXM, antibiotics with quite a small spectrum of activity,
where AMC- and/or CXM-resistant mutants or additional iso-
lates were frequently found. Furthermore, in our study, we
included two consecutive urine samples of a patient infected
withK. pneumoniae, of which DSTof the first sample showed
more resistance than AST for AMC® vs. S) and PPT (I vs. S).
In the second sample, however, AST agreed on the more re-
sistant DST results, thereby proving the initial false
susceptibility.
In polymicrobial specimens, isolates with similar pheno-
typic properties can be easily considered as one, especially
when present in small numbers. This phenomenon is well
illustrated in our study by a case of a polymicrobially infected
bile fluid, where AST revealed three species (E. coli,
K. oxytoca and P. aeruginosa), whilst DST revealed the pres-
ence of a fourth species (E. aerogenes) by discordance in
resistance to AMC, CXM, CTX, CAZ, SXT and OFL, each
R in DST and S in AST. The more resistant E. aerogenes was
cultured eventually in a follow-up sample taken 8 days later.
The clinical impact of DST was evaluated in a prospectively
and randomised study [25], showing a significantly higher
percentage of patients receiving an adequate defined daily
dose of therapy in the DST group (91.3 %) compared to the
AST group (68.3 %). Moreover, rapid identification and sus-
ceptibility testing has been shown to reduce the length of
hospitalisation of patients with sepsis, which translates into
reductions in the cost of patient care [22].
On the other hand, DST has several potential drawbacks,
including the likelihood of a non-interpretable DST with low
bacterial concentrations and ambiguities due to mixed cul-
tures. Due to the unstandardised inoculum in DST, it is hardly
surprising that strains showing susceptibility around the clin-
ical breakpoint can easily switch between interpretation cate-
gories. This is particularly the case in antibiotics having no
(AMC, CXM and FUR) or small (PPT) intermediate suscep-
tible category. In our experiments, this phenomenon was the
number two reason for discordant results. Moreover, all of the
five very major discordances ® in AST vs. S in DST) showed
a susceptibility close to the breakpoint (three FUR, one AMC
and one CXM). The issue of the unstandardised inoculum
could theoretically be circumvented by the use of Etests,
which contain a predefined stable gradient and are an
inoculum-tolerant system [2, 17]. However, as described
above, the results from studies using the Etest are equal to
those using disk diffusion. In addition, in case of co-infec-
tions, the readability of disk diffusion surpasses the Etest.
DST is not recommended by the ASM [22, 28], the BSAC
[23] nor the EUCAST [24], as the inoculum is unstandardised.
According to the ASM, DST of positive blood cultures and
urine is acceptable under certain conditions. First, microscopy
has to suggest a monomicrobial infection. Second, confirma-
tory AST has to be repeated once the organism is available in
pure culture. Next, laboratories should validate their method
against the standard results and DST results should only be
read by an experienced microbiologist. The BSAC acknowl-
edges the common practice of DST in many laboratories.
They suggest that a correct inoculum is achieved for urine
by using a sterile 10-μL loop and/or a sterile cotton swab for
blood cultures by placing one drop of broth in 5 mL of sterile
water, dependent on the results of the Gram stain. Besides,
they recommend tests to be repeated in case of non- or semi-
confluent growth, or mixed culture. The EUCAST stresses
that there are currently no validated methods for correct inoc-
ulums, but advocate a minimal incubation time of 16 h and
caution for visibly light inoculum, as strains could be reported
falsely susceptible. They claim that a reliable interpretation of
results requires a correct identification of the species and re-
peat testing on pure cultures. The EUCAST does not consider
automated systems suited for DST. Moreover, in general, they
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comment that any laboratory using this approach must take
responsibility for ensuring reliable results. In our approach,
most of these considerations are taken into account, with the
incorporation of rapid identification with MALDI-TOF MS.
Despite not having a solution for inoculum standardisation,
our results were very similar to the standard technique.
Our study has some limitations, especially as we did not
systematically analyse the impact of DST on antibiotic pre-
scription and clinical outcome. However, anecdotally, we
have found DST to be very useful in antibiotic decision-mak-
ing. Besides, we did not standardise the inoculum. In order to
demonstrate the wide applicability of DST, we included up to
six different sample types. Evidentially, not every category
was equally represented, resulting in limited data of certain
sample types.
In conclusion, DST on clinical samples is potentially very
useful in the management of critically ill patients, as the time
required for antibiotic sensitivity results is shortened by ap-
proximately 24 h. Rather than the susceptibility of one isolate,
DST reflects the microbial community in the sample, with
resistant mutants and additional isolates already visible. How-
ever, the results should be communicated as provisional and
confirmed by conventional AST. DST can be introduced in
laboratories using disk diffusion testing in a well-defined sam-
ple selection, such as the urine of patients with pyelonephritis
or even community-acquired cystitis, respiratory samples in
severe pneumonia, other severe infections and more general in
situations, regions or institutes with high resistance rates.
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